



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Mary et al

Examiner: L. Maier

Application No.: **10/849,356**

Art Unit: 1623

Filed: **May 19, 2004**

Title: **NOVEL THERAPEUTIC APPLICATION
OF ENOXAPARIN**

<p align="center">Certificate of Mailing or Transmission</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.</p> <p>Date of Deposit <u>August 26, 2004</u></p> <p>Printed Name of Person Signing Certificate <u>Bonnie Stein</u></p> <p>Signature <u>Bonnie Stein</u></p>
--

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
Washington, D.C. 20231


Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.


- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,


Irving Newman, 22,638
Attorney for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626
Aventis Docket No. USST00001US CNT



Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/849,356
Filing Date	05-19-2004
First Named Inventor	MARY
Group Art Unit	1623
Examiner Name	L. Maier
Attorney Docket Number	ST00001 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ADACHI et al, Alleviation of ischemic neuronal damage by posts ischemic loading with histidine in the rat striatum, Brain Res., Vol. 998, Issue 1, Feb., 2004, pp 136-138	
		CLARK et al, Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissue, Brain Res., Bull. Vol. 34, Issue 4, 1994, pp 387-392	
		DIETRICK, Morphological Manifestations of Reperfusion Injury in Brain, Ann. N.Y. Acad. Sci., Vol. 15, Issue 24, June, 1994, pp 15-24	
		KOGURE et al, Inflammation of the Brain after Ischemia, Acta Neurochir Suppl (Wien), Vol. 66, 1996, pp 40-43	
		McINTOSH et al, Effect of Noncompetitive Blockade of N-Methyl-D-Aspartate Receptors on the Neurochemical Sequelae of Experimental Brain Injury, Journal of Neurochemistry, Vol. 55, Issue 4, 1990, pp 1170-1179	
		TOULMOND et al, Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window, Brain Res., Vol. 620, 1993, pp 32-41	
		ZHANG et al, Aminoguanidine Ameliorates and L-Arginine Worsens Brain Damage From Intraluminal Middle Cerebral Artery Occlusion, Stroke, Vol. 27, No. 2, February, 1996, pp 317-323	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.